Edwards Lifesciences Stock News

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divestiture of non-core assets, new leadership, and a focus on high-growth hospital monitoring technologies. Eli Lilly remains a core holding due to its leadership in diabetes and obesity treatments, robu...

IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition by Edwards Lifesciences.

The U.S. Federal Trade Commission sued to block Edwards Lifesciences Corp's acquisition of JenaValve Technology Inc, saying in a lawsuit filed in Washington on Wednesday the merger would decrease competition in the market for a device meant to treat a potentially fatal heart condition.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Federal Trade Commission (FTC) moved to block the company's proposed acquisition of JenaValve Technology. Edwards disagrees with FTC's decision and believes it will limit the availability of an important treatment option for patients suffering from aortic regurgitation (AR). The company further believ...

Edwards Lifesciences Corporation (NYSE:EW ) Q2 2025 Earnings Conference Call July 24, 2025 5:00 PM ET Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Larry Wood - Corporate VP and Group President of TAVR & Surgical Structural Heart Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tr...

Edwards Lifesciences raised its 2025 sales forecast on Thursday, citing strong demand for its artificial heart valves and other medical devices, after posting better-than-expected results for the second quarter.

Edwards Lifesciences stock jumped late Thursday after the medtech company beat second-quarter forecasts and hiked its outlook.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and...